BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed cutaneous T-cell lymphoma (CTCL)
• * Any stage except IA patch only
• Previously treated according to 1 of the following:
• * Stage IA plaque, IB, or IIA:
• * At least 4 prior conventional and/or experimental regimens (topical or systemic, including psoralen-ultraviolet light \[PUVA\] and systemic corticosteroids)
• * Stage IIB, III, or IV:
• * At least 1 prior systemic regimen (systemic corticosteroids and PUVA do not count as systemic regimens for this purpose) NOTE: Repeated use of the same regimen is considered one regimen
• Measurable disease
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-3
• Life expectancy
• At least 3 months
• Hematopoietic
• Granulocyte count at least 2,000/mm\^3
• Platelet count at least 75,000/mm\^3
• Hemoglobin at least 10.0 g/dL
• Hepatic
• Bilirubin no greater than 1.5 times upper limit of normal (ULN) (unless due to Gilbert's syndrome)
• ALT no greater than 2 times ULN
• Alkaline phosphatase no greater than 2 times ULN
• No hepatitis B or C
• Renal
• Creatinine clearance at least 45 mL/min
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• Human T-cell leukemia virus type 1 (HTLV-1) negative
• No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
• No other illness that would limit study participation
• No active serious infection not controlled by antibiotics
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No concurrent anticancer antibody therapy
• No concurrent anticancer immunotherapy
• No concurrent anticancer gene therapy
• No concurrent anticancer vaccine therapy
• No concurrent anticancer angiogenesis inhibitors
• No concurrent sargramostim (GM-CSF)
• No concurrent filgrastim (G-CSF) during course 1 of therapy
• Chemotherapy
• More than 21 days since prior chemotherapy unless fully recovered
• No concurrent anticancer chemotherapy
• Endocrine therapy
• See Disease Characteristics
• More than 2 weeks since prior topical corticosteroids
• No concurrent anticancer hormonal therapy
• Radiotherapy
• More than 2 weeks since prior radiotherapy
• No concurrent radiotherapy
• Surgery
• Not specified
• Other
• More than 2 weeks since prior antineoplastic therapy
• More than 21 days since prior investigational agents unless fully recovered
• No concurrent citrate-blood products within 30 minutes before or after study treatment
• No concurrent anticancer matrix metalloprotease inhibitors
• No other concurrent anti-CTCL therapy
• No concurrent use of tanning beds
• No other concurrent investigational agents